Skin Cancer – Page 196

Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer

Background Immunotherapy, including adoptive cell therapy (ACT) and immune checkpoint inhibitors (ICIs), has a limited effect in most patients with colorectal cancer (CRC), and the efficacy is further limited in patients with liver metastasis. Lack of antitumor lymphocyte infiltration could be a major cause, and there remains an urgent need for more potent and safer… Continue reading Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer

It’s the Little Things: A Role for Bacteria in Cancer Treatment

Bacteria account for over 75% of the Earth’s population. And while we often think of these microbes as something to avoid (hand sanitizer, anyone?), emerging research suggests they could help us fight cancer. In several recent studies, genetically reprogrammed bacteria were able to boost antitumor immunity or enhance the effect of other cancer therapies, suggesting… Continue reading It’s the Little Things: A Role for Bacteria in Cancer Treatment

Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols

A retrospective analysis of patients diagnosed with head and neck squamous cell carcinoma at a National Cancer Institute-designated cancer center between 1998–2019 was performed . 50.6% of recurrences occurred within 6 months of treatment completion, 72.5% occurred in 1 year, 88.8% within 2 years . Oligometastatic disease treated with local ablative therapy was associated with… Continue reading Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols

Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols

Immunotherapy combination extends progression-free survival in patients with melanoma

A research team co-led by UCLA investigators has shown that an immunotherapy drug combination can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to the widely used immunotherapy drugs known as PD-1 inhibitors. In clinical trials, the investigators found that the combination therapy can extend… Continue reading Immunotherapy combination extends progression-free survival in patients with melanoma

Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor

Backgrounds Chimeric antigen receptor (CAR)-modified T cells (CAR-T) are limited in solid tumors due to the hostile tumor microenvironment (TME). Combination therapy could be a promising approach to overcome this obstacle. Recent studies have shown that sphingosine 1-phosphate receptor (S1PR)3 has tremendous potential in regulating the immune environment. However, the functional significance of S1PR3 in… Continue reading Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor

Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1

CT26 models were treated with anti-PD-1 on days 3, 6 and 9 following subcutaneous tumor implantation generating variable responses during early tumor development . Tetramer staining was performed to determine the frequency and avidity of CD8++ T cells targeting the tumor-specific epitope GSW11 and confirmed with tetramer competition assays . In vitro studies showed that… Continue reading Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1

TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy

Adoptive cell therapy (ACT) has shown promising results for the treatment of cancer and viral infections . Successful ACT relies on ex vivo expansion of large numbers of desired T-cells with strong cytotoxic capacity and in vivo persistence . Here, in this study, we present a novel technology for ex-vital expansion . artificial antigen-presenting scaffolds… Continue reading TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy

KLF12 overcomes anti-PD-1 resistance by reducing galectin-1 in cancer cells

Krüppel-like factor 12 (KLF12) is a transcriptional inhibitor whose role in tumor immunity is unclear . It suppresses CD8+ T cells infiltration and function in vitro and in vivo . Mechanistically, it inhibits the expression of Gal-1 by binding with its promoter . This may serve as a novel therapeutic target for patients with immunotherapy resistance… Continue reading KLF12 overcomes anti-PD-1 resistance by reducing galectin-1 in cancer cells

Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma

Combination therapy with radioembolization (yttrium-90)-resin microspheres followed by nivolumab has shown a promising response rate of 30.6% in a Phase II trial (CA209-678) for advanced hepatocellular carcinoma (HCC) The response mechanisms and relevant biomarkers remain unknown .